Noncovalent PEGylation, An Innovative Subchapter in the Field of Protein Modification

Journal of Pharmaceutical Sciences

Volumn 105, Issue 2, 2016, Pages 386-390

  Reichert, Christian ^a   Borchard, Gerrit ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

drug delivery; noncovalent PEGylation; pegylation; protein aggregation; protein drugs; protein formulation; proteins; stabilization

Indexed keywords

ASPARAGINASE; DRUG CARRIER; MACROGOL; POLYELECTROLYTE; SALCATONIN; MACROGOL DERIVATIVE;

BINDING AFFINITY; CHEMICAL REACTION; CHEMICAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG HALF LIFE; ENZYME ACTIVITY; IMMUNE SYSTEM; IMMUNOGENICITY; PHARMACOKINETIC PARAMETERS; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN MODIFICATION; REVIEW; SHELF LIFE; STEREOSPECIFICITY; URINARY EXCRETION; ANIMAL; CHEMISTRY; HUMAN; INVENTION; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; TRENDS;

ANIMALS; HUMANS; INVENTIONS; POLYETHYLENE GLYCOLS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84949257679     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24692     Document Type: Short Survey

References (31)

1. B. Leader, Q.J. Baca, and D.E. Golan Protein therapeutics: A summary and pharmacological classification Nat Rev Drug Discov 7 2008 21 39
2. S. Ohtake, Y. Kita, and T. Arakawa Interactions of formulation excipients with proteins in solution and in the dried state Adv Drug Deliv Rev 63 2011 1053 1073
3. T.J. Kamerzell, R. Esfandiary, S.B. Joshi, C.R. Middaugh, and D.B. Volkin Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development Adv Drug Deliv Rev 63 2011 1118 1159
4. M.J. Akers Excipient-drug interactions in parenteral formulations J Pharm Sci 91 2002 2283 2300
5. N.V. Dovidchenko, E.I. Leonova, and O.V. Galzitskaya Mechanisms of amyloid fibril formation Biochem Moscow 79 2014 1515 1527
6. W. Wang, S.K. Singh, N. Li, M.R. Toler, K.R. King, and S. Nema Immunogenicity of protein aggregates - Concerns and realities Int J Pharm 431 2012 1 11
7. A. Rosenberg Effects of protein aggregates: An immunologic perspective AAPS J 8 2006 E501 E507
8. X. Tang, and M. Pikal Design of freeze-drying processes for pharmaceuticals: Practical advice Pharm Res 21 2004 191 200
9. J.C. Kasper, and W. Friess The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals Eur J Pharm Biopharm 78 2011 248 263
10. M. Hamidi, A. Azadi, and P. Rafiei Pharmacokinetic consequences of pegylation Drug Deliv 13 2006 399 409
11. F. Veronese, and A. Mero The impact of PEGylation on biological therapies BioDrugs 22 2008 315 329
12. A. Abuchowski, T. van Es, N.C. Palczuk, and F.F. Davis Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J Biolog Chem 252 1977 3578 3581
13. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, and F.F. Davis Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J Biolog Chem 252 1977 3582 3586
14. P. Caliceti, and F.M. Veronese Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv Drug Deliv Rev 55 2003 1261 1277
15. P. Caliceti, F.M. Veronese, and Z. Jonak Immunogenic and tolerogenic properties of monomethoxypoly(ethylene glycol) conjugated proteins Farmaco 54 1999 430 437
16. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov Today 10 2005 1451 1458
17. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat Rev Drug Discov 2 2003 214 221
18. C.S. Fishburn The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics J Pharm Sci 97 2008 4167 4183
19. T. Peleg-Shulman, H. Tsubery, M. Mironchik, M. Fridkin, G. Schreiber, and Y. Shechter Reversible PEGylation: A novel technology to release native interferon α2 over a prolonged time period J Med Chem 47 2004 4897 4904
20. H. Tsubery, M. Mironchik, M. Fridkin, and Y. Shechter Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification J Biolog Chem 279 2004 38118 38124
21. H. Zhao, K. Yang, A. Martinez, A. Basu, R. Chintala, H.-C. Liu, A. Janjua, M. Wang, and D. Filpula Linear and branched bicin linkers for releasable PEGylation of macromolecules: Controlled release in vivo and in vitro from mono- and multi-PEGylated proteins Bioconjug Chem 17 2006 341 351
22. G. Pasut, A. Mero, F. Caboi, S. Scaramuzza, L. Sollai, and F.M. Veronese A new PEG-β-alanine active derivative for releasable protein conjugation Bioconjug Chem 19 2008 2427 2431
23. R.B. Greenwald, K. Yang, H. Zhao, C.D. Conover, S. Lee, and D. Filpula Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination Bioconjug Chem 14 2003 395 403
24. D. Filpula, and H. Zhao Releasable PEGylation of proteins with customized linkers Adv Drug Deliv Rev 60 2008 29 49
25. C. Mueller, M.A.H. Capelle, T. Arvinte, E. Seyrek, and G. Borchard Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin J Pharm Sci 100 2011 1648 1662
26. C. Mueller, M.A.H. Capelle, T. Arvinte, E. Seyrek, and G. Borchard Tryptophan-mPEGs: Novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation Eur J Pharm Biopharm 79 2011 646 657
27. C. Mueller, M.A.H. Capelle, E. Seyrek, S. Martel, P.-A. Carrupt, T. Arvinte, and G. Borchard Noncovalent PEGylation: Different effects of dansyl-, l-tryptophan-, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme J Pharm Sci 101 2012 1995 2008
28. A. Mero, T. Ishino, I. Chaiken, F. Veronese, and G. Pasut Multivalent and flexible PEG-nitrilotriacetic acid derivatives for non-covalent protein pegylation Pharm Res 28 2011 2412 2421
29. S. Khondee, C.M. Olsen, Y. Zeng, C.R. Middaugh, and C. Berkland Noncovalent PEGylation by polyanion complexation as a means to stabilize keratinocyte growth factor-2 (KGF-2) Biomacromolecules 12 2011 3880 3894
30. H. Fan, S.N. Vitharana, T. Chen, D. O'Keefe, and C.R. Middaugh Effects of pH and polyanions on the thermal stability of fibroblast growth factor 20 Mol Pharm 4 2007 232 240
31. T. Kurinomaru, and K. Shiraki Noncovalent PEGylation of l-asparaginase using PEGylated polyelectrolyte J Pharm Sci 104 2015 587 592